Idorsia advances daridorexant development for autism spectrum disorder

• Idorsia will launch a new daridorexant development program in autism spectrum disorder following exploratory findings from a Phase 2 pediatric insomnia study.
• The placebo-controlled trial enrolled 165 children and adolescents; participants with autism or subthreshold characteristics showed improvements in daytime functioning beyond sleep.
• Daridorexant 50 mg showed improvements in behavior, cognition and daily activities within two weeks, but the exploratory findings require prospective confirmation.
• Sleep findings were already presented at Sleep Europe 2026; the autism analysis was presented at the Society for Developmental and Behavioral Pediatrics meeting.
• A dedicated formulation is in development, with program details expected in the first half of 2027 following health authority discussions.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Idorsia Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610260200OMX_____CNEWS_EN_GNW1001279769_en) on October 26, 2026, and is solely responsible for the information contained therein.